Climb Bio, Inc.

What they do

Climb Bio is developing budoprutug, an anti-CD19 monoclonal antibody, for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). It also in-licensed CLYM116, an anti-APRIL antibody, from Beijing Mabworks Biotech for development outside Greater China. The company has worldwide rights to budoprutug for all indications except oncology.

Revenue drivers

• Budoprutug (pMN, ITP, SLE) — Lead product candidate, in Phase 2 for pMN, Phase 1b/2a for ITP and SLE; no revenue yet, costs funded by cash and financing.
• CLYM116 (IgA nephropathy) — In-licensed anti-APRIL antibody, Phase 1 data expected; Phase 2 in IgAN to start Q3 2026; no revenue.
• No product sales — No regulatory approvals or product revenue to date; all income from financing (e.g., equity raises).

Recent performance

Net loss was $59.9 million in 2025, compared to $73.9 million in 2024; diluted EPS was -$0.88 versus -$1.53. Operating cash flow was -$54.4 million in 2025. As of June 30, 2026, cash and equivalents were $44.1 million, total assets $246.3 million, and shareholder equity $239.5 million. The company has not generated any revenue.

Strategy

Climb Bio is advancing budoprutug through Phase 2 in pMN and Phase 1b/2a in ITP and SLE, with data readouts expected in Q4 2026. It plans to initiate a Phase 2 trial of CLYM116 in IgA nephropathy in Q3 2026. The company is presenting CLYM116 Phase 1 data at an R&D Spotlight on September 3, 2026. Management aims to move both programs toward pivotal development, with financing extending cash runway into the second half of 2028.

Risks

• Clinical development risk — Budoprutug and CLYM116 are early-stage; Phase 2 and Phase 1b/2a trials may fail to meet endpoints.
• No revenue and reliance on funding — No approved products or revenue; continued losses and negative operating cash flow require additional financing to sustain operations beyond 2028.
• Regulatory and competitive risk — pMN has no approved therapies, but competing CD19 and anti-APRIL programs could affect market opportunity; FDA designations do not guarantee approval.
• Intellectual property and licensing risk — Rights to budoprutug and CLYM116 are acquired or in-licensed; any breach or termination of agreements could limit development.

Outlook

Management expects initial PrisMN Phase 2 data (low-dose cohort) in Q4 2026, and additional ITP data from 500mg and 1000mg cohorts in Q4 2026. CLYM116 Phase 1 data will be presented in September 2026, with Phase 2 dosing in IgAN expected to begin in Q3 2026. The company believes its cash runway extends into the second half of 2028, supporting advancement toward pivotal development.